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Once in a while a paper comes along which, while reinforcing established wisdom, does so in 
a manner which is potentially clinically impactful. The paper by Brownrigg et al (1), which 
takes advantage of the excellent Clinical Practice Research Datalink (CPRD) to examine the 
associations of microvascular complications with cardiovascular risk, heart failure 
hospitalisation and all-cause mortality in patients with type 2 diabetes, does just this. Its 
simple message is that the presence of any microvascular disease, namely neuropathy, 
retinopathy and/or nephropathy, signals risk for cardiovascular disease which is sufficient to 
warrant robust preventative therapy; indeed, individual microvascular complications 
appeared to better indicate cardiovascular risk than did individual classical risk factors. More 
notably, cardiovascular risk appeared to escalate in a graded, almost linear, fashion with 
increasing numbers of microvascular complications such that the simultaneous presence of 
retinopathy, nephropathy and neuropathy was associated with twice the risk for 
cardiovascular events compared to those with no such complications in analyses adjusted for 
not only classical risk factors but also lipid-lowering and anti-hypertensive therapy (1). 
Multiple microvascular complications signalled even higher risks for both cardiovascular 
death and heart failure hospitalisation, a finding which in itself deserves further study. The 
authors cogently argue that the presence of multiple microvascular complications should 
encourage intensification of cardiovascular protective therapies. Such findings are not 
surprising if we consider that microvascular complications typically develop over several 
years (although the findings were robust to adjustment for the duration of diabetes) and that 
hypertension is also a strong risk factor for both diabetic retinopathy and renal disease. Nor 
should the results be a surprise on mechanistic grounds as there is now ample evidence that 
pathophysiological processes leading to microvascular damage in part mirror, or directly 
contribute to, macrovascular damage (2).  
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A key question with any such evidence is whether the findings can truly improve clinical 
practice. With this in mind, it is notable that statin in CPRD use was above 70% in subjects 
with any microvascular complications while more than 85% were receiving blood pressure 
treatment, and corresponding cholesterol and blood pressure levels were excellent. These 
treatment figures are high in CPRD since NICE guidelines recommend statins to all adults 
above 40 years of age with type 2 diabetes, and that SBP should be <140 to lessen CVD 
risks, the latter target supported by a recent meta-analysis (3).  Only in England and Wales 
have the health authorities (National Institute of Clinical Excellence) recently recommended 
reverting to cardiovascular risk scoring to determine which diabetic patients should receive 
statins for primary prevention (4). In this latter case, as well as the US-based ACC/AHA 
cardiovascular  risk score (5) (used to determine which diabetic patients should be escalated 
to more intensive statin therapy), Brownrigg et al (1) show that adding information on 
microvascular complications could meaningfully improve allocation of moderate or intensive 
dose statins. The caveat to this is that primary prevention cardiovascular risk scores 
commonly used in most countries do not include diabetes-specific factors such as HbA1c or 
duration of diabetes, and though diabetes specific risk scores do exist (6), it appears that such 
risk scores are unlikely to gain widespread clinical use because of their complexity and the 
widening use of generically available statins.   
Rather, we suggest the current findings may help in three simpler ways.  Firstly, the findings 
should strongly reinforce the need to commence statin therapy and aggressively pursue 
recommended blood pressure targets in any patients not already on such therapies with any 
microvascular damage, particularly patients younger than 40 years of age in whom guidelines 
are often less prescriptive.  Secondly, microvascular disease in more than one vascular bed 
(e.g. retinopathy plus neuropathy) should prompt consideration of more intensive lipid-
lowering therapy to achieve lower LDL-c (or non-HDL-c) targets. Notably, the recently 
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published European Society of Cardiology cardiovascular prevention guidelines (7) already 
categorise “diabetes with target organ damage such as proteinuria” as conveying very high 
risk for cardiovascular disease and thus supporting lower LDL-c targets. Of all the 
microvascular complications, the present paper in conjunction with prior studies (8) 
reinforces the notion that diabetes plus microalbuminuria is commensurate with markedly 
elevated cardiovascular risk. Thirdly, the paper’s findings could help those designing trials in 
patients with diabetes looking to enrich their population in terms of cardiovascular risk or, 
more specifically, cardiovascular death and heart failure risks.  
Finally, it must be borne in mind that while cardiovascular event rates in patients with 
diabetes in high income countries have decreased sharply in the last two decades, concerns 
remain with respect to complications like end-stage renal failure and heart failure (9). To 
mitigate against these will require more aggressive management of microvascular damage per 
se which would mean aiming for: i. Lower SBP targets (<130mmHg) in selected groups, ii. 
Earlier detection of diabetes and more aggressive glycaemia management early after 
diagnosis, and iii. The earlier use of drug classes proven to do more than just lower glucose 
levels. Fortunately, though higher costs will limit their usage, two more recent additions to 
the diabetes armoury (GLP-1 receptor antagonists and SGLT2 inhibitors) fulfil this latter 
characteristic and thus meaningfully add to the tool box of diabetes medications.  
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